

Yellow Fever Training - Course Reference

1. World Health Organization. Informal Working Group on Geographic Risk of Yellow Fever. Background for the Consultation on Yellow Fever and International Travel, 2010: February, Stockholm, 2011. Available at: <http://www.who.int/ith/YFrisk.pdf>
2. Monath T. YF: an update. *The Lancet Infectious Diseases* 1: 11-20, 2001
3. Heyman D, (ed.). *Control of Communicable Diseases Manual*. 18th edn. Washington; American Public Health Association: 2004
4. US Centers for Disease Control and Prevention. Yellow Fever. Ch 3. In: *Health Information for International Travel*. 2017. Available at: <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever>
5. European Centre for Disease Prevention and Control. Rapid Risk Assessment Yellow fever among travellers returning from South America. 14 March 2017. Available at: <http://ecdc.europa.eu/en/publications/Publications/14-03-2017-RRA-Yellow%20fever,%20Flaviviridae-Suriname,%20Southern%20America.pdf>
6. Monath T.P Gershman M, Staples J.E. & Barrett A.D. Yellow fever vaccine Ch 38 in *Vaccines 6th Edition*, Edited by Plotkin S.A. Orenstein W.A. & Offit P.A. Elsevier Saunders, 2013.
7. World Health Organization. Background Paper on Yellow Fever Vaccine. SAGE Working Group 19th March 2013. Available at: http://www.who.int/immunization/sage/meetings/2013/april/1_Background_Paper_Yellow_Fever_Vaccines.pdf
8. World Health Organization. Vaccines and vaccination against yellow fever. WHO Position Paper - June 2013; 88, 269-284 Available at <http://www.who.int/wer/2013/wer8827.pdf?ua=1>
9. Sanofi Pasteur. Summary of Product Characteristics – Stamaril. Updated 23 March 2017. Available at: <http://www.medicines.org.uk/emc/medicine/9846>
10. Public Health England. Chapter 4 Immunisation Procedures. Immunisation against infectious disease. Updated chapter available at: <https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4>
11. Public Health England. Chapter 35 Yellow fever. Immunisation against infectious disease. Updated chapter available at: <https://www.gov.uk/government/publications/yellow-fever-the-green-book-chapter-35>
12. Centers for Disease Control and Prevention. Transmission of yellow fever vaccine virus through breast feeding – Brazil, 2009. *MMWR*: 59(05); 130-132, 2010. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5905a2.htm>

13. World Health Organization. Global Advisory Committee on Vaccine Safety, Wkly Epidemiol Rec. 16–17 June 2010; July 23; 30(85): 285-292, 2010. Available at: <http://www.who.int/wer/2010/wer8530.pdf>
14. Kuhn S, Twele-Montecinos L, MacDonald J et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ; March 8; 183(4): E243-E245, 2011. Available at: <http://www.ecmaj.ca/content/183/4/E243.full.pdf+html>
15. Suzano CES, Amaral E, Sato HK et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine; 24(9): 1421-1426, 2006.
16. Geretti AM. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med; Nov; 9(10):795-848, 2008. Available at: <http://www.bhiva.org/documents/Guidelines/Immunisation/Immunization2008.pdf>
17. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine; 23: 3256–63, 2005
18. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Clin Immunol; 103:698, 1999
19. Centers for Disease Control and Prevention. Adverse events associated with 17D- derived yellow fever vaccination - United States, 2001-2002. MMWR; 51: 989-993, 2002. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5144a1.htm>
20. Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine; 26(48):6077-6082, 2008
21. Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet; September 11; 364(9438): 936, 2004
22. MMWR. Yellow Fever: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). July 30, 2010:59(RR07);1-27, 2010. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf>
23. Martin M, Weld LH, Tsai TF, et al. GeoSentinel Yellow Fever Working Group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis; 7(6): 945-51, 2001
24. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme. Available at: <https://yellowcard.mhra.gov.uk/>
25. Sanofi Pasteur MSD UK Adverse Event Reporting Form. Available at: <http://www.spmsd.co.uk/ae/>



26. NaTHNaC Clinical Information. Reporting suspected yellow fever vaccine- associated neurologic disease (YEL-AND) or suspected yellow fever vaccine- associated viscerotropic disease (YEL-AVD); 29 June, 2009. Available at: http://www.nathnac.org/yf_centres/YFadverseevents.htm

27. Gershman M.D. Staples J.E. Yellow fever. In Health Information for International Travel 2016, Chapter 3, 346-360, Centres for Disease Control and Prevention (CDC), Oxford university press. Also available at: <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever>